Evidence map›Paper›PMID 38240353›Full record

ArticleJournal of cell science2024

The Drosophila tumour suppressor Lgl and Vap33 activate the Hippo pathway through a dual mechanism.

Marta Portela, Swastik Mukherjee, Sayantanee Paul, John E La Marca, Linda M Parsons, Alexey Veraksa, Helena E Richardson

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cell science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Marta PortelaDepartment of Biochemistry & Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, 3086, Australia.
Swastik MukherjeeDepartment of Biology, University of Massachusetts Boston, Boston, MA 02125, USA.
Sayantanee PaulDepartment of Biology, University of Massachusetts Boston, Boston, MA 02125, USA.
John E La MarcaDepartment of Biochemistry & Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, 3086, Australia.
Linda M ParsonsCell Cycle and Development Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, 3002, Australia.
Alexey VeraksaDepartment of Biology, University of Massachusetts Boston, Boston, MA 02125, USA.ORCID 0000-0003-2920-080X
Helena E RichardsonDepartment of Biochemistry & Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, 3086, Australia.ORCID 0000-0003-3852-4953
University of Massachusetts Boston · USThe University of Melbourne · AULa Trobe University · AUPeter MacCallum Cancer Centre · AU

Funding

Cytoplasmic and transcriptional control of Hippo signalingR01GM123136 · NIGMS · EMORY UNIVERSITY · PI MOBERG, KENNETH H, VERAKSA, ALEXEY · 2018 to 2021
$1.2M
NIGMS NIH HHS R01 GM123136NIH HHS GM123136
6 · The paper itself

Abstract

The tumour suppressor, Lethal (2) giant larvae [Lgl; also known as L(2)gl], is an evolutionarily conserved protein that was discovered in the vinegar fly Drosophila, where its depletion results in tissue overgrowth and loss of cell polarity. Lgl links cell polarity and tissue growth through regulation of the Notch and the Hippo signalling pathways. Lgl regulates the Notch pathway by inhibiting V-ATPase activity via Vap33. How Lgl regulates the Hippo pathway was unclear. In this current study, we show that V-ATPase activity inhibits the Hippo pathway, whereas Vap33 acts to activate Hippo signalling. Vap33 physically and genetically interacts with the actin cytoskeletal regulators RtGEF (Pix) and Git, which also bind to the Hippo protein (Hpo) and are involved in the activation of the Hippo pathway. Additionally, we show that the ADP ribosylation factor Arf79F (Arf1), which is a Hpo interactor, is involved in the inhibition of the Hippo pathway. Altogether, our data suggest that Lgl acts via Vap33 to activate the Hippo pathway by a dual mechanism: (1) through interaction with RtGEF, Git and Arf79F, and (2) through interaction and inhibition of the V-ATPase, thereby controlling epithelial tissue growth.

Indexed as

Drosophila ProteinsNeoplasmsAdenosine TriphosphatasesAnimalsCarrier ProteinsCell PolarityDrosophilaDrosophila melanogasterHippo Signaling PathwayIntracellular Signaling Peptides and ProteinsMembrane ProteinsProtein Serine-Threonine KinasesSignal TransductionTumor Suppressor ProteinsAdenosine TriphosphatasesCarrier ProteinsDrosophila ProteinsIntracellular Signaling Peptides and Proteinsl(2)gl protein, DrosophilaMembrane ProteinsProtein Serine-Threonine KinasesTumor Suppressor ProteinsVap33 protein, DrosophilaArf79FDrosophilaGitHippo pathwaylglRtGEFVap33V-ATPase

Identifiers

PMID38240353
PMCPMC10911279
OpenAlexW4391027113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.